PD1 x VEGF bispecific landscape: examining Hope versus Hype.
There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics.